Purpose | Dosage Range | Frequency | Administration |
---|---|---|---|
Tanning | 0.01-0.03 mg/kg | Every other day | Subcutaneous injection |
Sexual Dysfunction | 0.025-0.03 mg/kg | As needed | Subcutaneous injection |
Research | 0.01-0.05 mg/kg | As per protocol | Subcutaneous injection |
2. What is Melanotan II?
Chemical formula: C50H69N15O9
Molecular weight: 1024.2 g/mol
Sequence: Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2
Cyclic heptapeptide structure
Developed at the University of Arizona in the 1980s
Not approved for human use by regulatory agencies
Binds to and activates melanocortin receptors (MC1R, MC3R, MC4R, MC5R)
Stimulates melanogenesis in skin melanocytes
Increases production of eumelanin, leading to skin darkening
Affects sexual arousal through central nervous system effects
Influences appetite and metabolism via MC4R activation
May have effects on the cardiovascular and immune systems
Induces melanogenesis without UV exposure
Potential for reducing UV-induced skin damage
May lower risk of skin cancer (theoretical, not proven)
Potential treatment for erectile dysfunction
May increase sexual arousal in both men and women
Possible application in weight management
Affects food intake through MC4R activation
Potential treatment for vitiligo and other hypopigmentation disorders
May have applications in photoprotection
Starting dose: 0.01 mg/kg
Maintenance dose: 0.02-0.03 mg/kg
Administered every other day for 2-3 weeks
Typical dose: 0.025-0.03 mg/kg
Administered as needed, 1-2 hours before sexual activity
Dose range: 0.01-0.05 mg/kg
Frequency depends on research protocol
Reconstitute lyophilized Melanotan II with bacteriostatic water
Use sterile injection materials
Calculate dosage based on body weight
Draw correct amount into insulin syringe
Administer via subcutaneous injection
Most common method
Inject into fatty tissue of abdomen or thigh
Rotate injection sites
Less common, but used by some
May have lower bioavailability compared to injection
May enhance tanning effects
Caution advised due to potential increased skin cancer risk
Potential for enhanced effects on erectile function
Caution advised due to risk of priapism
Changes in size and pigmentation of existing moles
Potential increased risk of melanoma
Renal dysfunction and rhabdomyolysis
Cardiovascular effects (e.g., increased blood pressure)
Nausea, facial flushing, and fatigue
Potential for abuse and addiction
Risk of contamination in unregulated products
Not approved by the FDA or other major regulatory agencies for human use
Legal status varies by country and jurisdiction
Often restricted to research use only
Sale for human consumption is illegal in many countries
Possession may be legal in some areas, but use is strongly discouraged
Store lyophilized powder at -20°C (-4°F)
Once reconstituted, store in refrigerator (2-8°C or 36-46°F)
Use within 30-60 days after reconstitution
Protect from light and excessive heat
Always use sterile techniques when handling
Effects may be noticeable within 5-7 doses, with maximum effect typically seen after 2-3 weeks of regular use.
Long-term use is not recommended due to potential health risks and lack of safety data.
While it may theoretically reduce UV damage, there's no evidence that it protects against skin cancer, and it may increase the risk of melanoma.
Safer alternatives include gradual self-tanning products and controlled UV exposure with proper sun protection.
While Melanotan II has shown potential effects on tanning and sexual function, its use is associated with significant risks and is not recommended for human use outside of controlled research settings. The lack of regulation, potential for serious side effects, and unknown long-term consequences make it a dangerous substance for personal use. Individuals seeking tanning or treatment for sexual dysfunction should consult with healthcare professionals for safe, approved alternatives.
Brennan R, et al. (2017). Melanotan II use in the general population. BMJ Case Rep, 2017, bcr2017221301.
Langan EA, et al. (2010). Melanotan: the perils of an unlicensed drug. BMJ, 340, c2305.
Nelson ME, et al. (2019). The abuse liability and clinical pharmacokinetics of intranasal melanotan-II. Drug Alcohol Depend, 201, 89-96.
Ong S, Bowling J. (2012). Melanotan-associated melanoma in situ. Australas J Dermatol, 53(4), 301-302.
Therapeutic Goods Administration. (2018). Scheduling delegates' interim decisions and invitation for further comment: ACCS/ACMS, November 2017.
Disclaimer
Peptideresearcher.com contains information about products intended for research and laboratory use only, unless otherwise explicitly stated. All content is for educational purposes and is not meant to substitute for professional medical advice. Peptideresearcher.com strives to ensure that all information presented is accurate and complies with national and international standards, but it is not guaranteed. The content provided is not intended to diagnose, treat, cure, or prevent any disease or condition.
Peptideresearcher.com does not offer medical diagnoses or prescriptions. Any product information shared is solely for research purposes and should be used by qualified professionals only. We advise all users to consult with a healthcare professional before using any peptides, supplements, or medications mentioned on this site. All opinions expressed are those of the individual authors and may not reflect the opinions of Peptideresearcher.com.
Copyright 2024 - Peptide Researcher
Your access to Peptideresearcher.com is subject to our Terms of Use